Clinical Trials Logo

Clinical Trial Summary

Epidermal growth factor receptor inhibitors (EGFRIs) are widely used targeted agents that have been approved for the treatment of various tumor types. In some clinical studies with EGFRIs, the incidence of dermatology AE, the skin rash, is reportedly as high as 95%, which profoundly impact the patients' quality of life. However no treament for onset skin rash has been approved to be effective by any clinical trial yet. Janus kinase (JAK) inhibitor, has been approved for or studied in a variety of skin conditions such as alopecia areata, atopic dermatitis, and psoriasis. Thus the investigators intend to evaluate the efficacy and safety of JAK inhibitor cream for the treatment of EGFRIs-induced skin rash in cancer patients.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05120362
Study type Interventional
Source Shanghai East Hospital
Contact Nan Xu, M.D.
Phone +86-15520893298
Email [email protected]
Status Recruiting
Phase N/A
Start date November 2021
Completion date April 2022

See also
  Status Clinical Trial Phase
Recruiting NCT04864717 - Doxycycline vs Isotretinoin for Acneiform Eruptions of TKI Phase 4
Recruiting NCT04697069 - Evaluation of the Efficacy and Safety of ANB019 in the Treatment of Acneiform Rash Phase 2